LDL receptor related protein 12Genealiases: ALS28 · MIG13A · ST7
Q-omics provides the consensus-scored LRP12 profile across patient tissues and cancer cell-line models. LRP12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRP12 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LRP12 RNA expression shows 20,783 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where LRP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRP12 survival associations across molecular data types. LRP12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRP12 RNA expression–survival associations across cancer types. High LRP12 expression shows unfavorable associations in UVM, STAD, ACC, BLCA, LIHC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRP12 RNA expression.
This table summarizes LRP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRP12 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LIHC, LUSC, LUAD and CHOL. The HNSC box plot shows higher LRP12 RNA expression in tumor versus normal tissue (log2 FC = +2.073, t-test p < 0.001).
This table shows molecular features associated with LRP12 in patient tissues and cancer cell lines. In patient samples, LRP12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRP12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
